12 results about "Ornidazole" patented technology

The application belongs to the technical field of medicine synthesis and provides a preparation method of phosphonic acid levomoxiflazine disodium, which comprises the following steps: taking levomoxiflazine as raw material, performing esterification through phosphorus oxychloride and hydrolysis to obtain a reaction solution containing phosphonic acid levomoxiflazine; slowly and uniformly adding a sodium hydroxide methanol solution, first adjusting pH to 6.3-7.6, filtering out impurities, then adjusting pH to 9.1-9.8, crystallizing and drying to obtain a crude product; and performing recrystallization through a water-ethanol-acetone mixed system, filtering and drying to obtain a high-purity product. The application solves the problems of high impurity content and low yield in the prior art by optimizing the amount of esterification reagent, the pH adjustment mode and the recrystallization system, the HPLC purity of the obtained phosphonic acid levomoxiflazine disodium is greater than or equal to 99.97%, the maximum single impurity content is less than or equal to 0.02%, the process is simple, easy to operate, stable and suitable for industrial amplification production.

The application aims to provide a preparation method of high-purity phosphonic acid levonikosazol ester disodium hydrate, which has the advantages of controllable reaction condition, stable quality, high yield and suitability for industrial production, etc.

The present application relates to the technical field of chemical medicine preparation, and particularly discloses a freeze-drying method of injection phosphonic acid left-onitrazole ester disodium freeze-dried product. The present application pre-freezes phosphonic acid left-onitrazole ester disodium liquid at-20℃ to-15℃, freezes the obtained suspension material at-60℃ to-40℃ to obtain frozen solid, sublimates and dries the frozen solid at-12℃ to-8℃, and analyzes and dries at 15℃ to 25℃ to obtain injection phosphonic acid left-onitrazole ester disodium freeze-dried product. In the pre-freezing stage, the phosphonic acid left-onitrazole ester disodium liquid gradually changes from liquid to suspension material with uniform solute, and the solute is not frozen solid; in the freezing stage, the suspension material is gradually frozen solid; in the sublimation drying stage, the free water in the material is removed by one-stage heating, which greatly shortens the freeze-drying time; finally, the bound water in the material is removed in the analysis stage, and the moisture and impurity content in the freeze-dried product are lower.

The present invention relates to the field of organic chemical synthesis, and particularly to a preparation method of ornidazole. The preparation method includes four steps: chiral thiourea-catalyzed Henry reaction, Suzuki coupling reaction, nitro reduction reaction, and tetrazole cyclization reaction, to obtain the target product with high yield and enantioselectivity. This method has good application prospects in the industrial production of ornidazole, is expected to reduce production costs and improve product quality, so as to meet the production requirements.

The utility model discloses a sampling device for ornidazole raw material medicine, and belongs to the technical field of ornidazole production. The sampling device for the ornidazole bulk drug further comprises a button embedded in the upper end of the pull rod, the upper end of the pull rod is fixedly connected with a pressing plate; a motor is embedded in the lower end of the pull rod; the output end of the motor penetrates through the lower sealing plate and then is fixedly connected with fan blades. The lower side of the shell is slidably connected with the storage tank; a spring II is arranged between the shell and the storage tank; the shell is elastically connected with the storage tank through a spring II; a spring I is arranged between the shell and the pull rod; the shell is elastically connected with the pull rod through a spring I; by arranging the motor and the fan blades, the fan blades are used for pushing away the bulk drugs on the upper layer, the bulk drugs are conveniently and uniformly extracted, and the sampling effect is improved.

1.The name of the design product: packaging box (ornidazole injection). 2.The use of the design product: the design product is used for the outer packaging of ornidazole injection. 3.The design points of the design product: the combination of shape, pattern and color. 4.The picture or photo that best shows the design points: front view. 5.The design claimed contains color.

The invention discloses a pharmaceutical composition containing an ornidazole compound as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises an ornidazole compound and 1-(2, 3-epoxypropane)-2-methyl-5-nitroimidazole, wherein the content of the 1-(2, 3-epoxypropane)-2-methyl-5-nitroimidazole is 1000 mg / kg or below. The safety and / or stability of the pharmaceutical composition in the period of validity are / is remarkably improved.

The invention discloses a bio-responsive drug-loaded micelle targeting fusobacterium nucleatum as well as a preparation method and application of the bio-responsive drug-loaded micelle, and relates to the field of biomedicine. The preparation method comprises the following steps: firstly, synthesizing block copolymers PBA-PEG-b-PCL and GalNAc-PAE-b-PCL; then, calcipotriol (Cal) and ornidazole (ONZ) are connected through a disulfide bond, and a conjugate Cal-ONZ is prepared; the two segmented copolymers are used for self-assembly and loading of Cal-ONZ, and the drug-loaded nano micelle C-O (at) CPM-GalNAc is obtained. The micelle can realize targeted removal of fusobacterium nucleatum and release of a matrix barrier in a tumor microenvironment, and by constructing an immune transfer closed loop infiltrated and activated by T cells, the anti-tumor immune response is remarkably enhanced, and the curative effect of an alphaPD-L1 checkpoint inhibitor is improved. The strategy is expected to provide a new solution for colorectal cancer immunotherapy related to fusobacterium nucleatum.

The invention relates to a S-ornidazole disodium phosphate hexahydrate crystal form and a preparation method thereof.The X-ray powder diffraction pattern of S-ornidazole disodium phosphate hexahydrate has characteristic peaks at 6.1, 15.1, 15.9, 24.2, 25.6, 26.3, 27.1, 32.7 and 34.3. The S-ornidazole disodium phosphate hexahydrate crystal form obtained through the method is high in purity, the preparation method is simple, and the S-ornidazole disodium phosphate hexahydrate crystal form is suitable for industrial production.

The invention relates to a pet spray and a preparation method thereof. The spray for pets comprises the following raw material components: a traditional Chinese medicine component, a western medicine component and a pH buffer solution, the traditional Chinese medicine components comprise the following components in parts by weight: 0.1-1 part of tea polyphenol, 1-15 parts of chlorogenic acid and 0.1-1 part of menthol; the western medicine component accounts for 1-15 parts and comprises the following components in parts by weight: 1-10 parts of ornidazole, 0.1-2 parts of lincomycin, 0.1-0.5 part of mometasone furoate and 0.1-2 parts of vitamin B2; and the pH buffer solution accounts for 58-96 parts. The spray for the pets contains the traditional Chinese medicine components, the western medicine components and the buffer solution, the synergistic effect between the traditional Chinese medicine components and the western medicine components can be fully exerted, and when the spray is used for preventing and treating oral diseases, the effective medicine utilization degree is high, the effect is good, and drug resistance is not prone to being generated.

The invention relates to a pharmaceutical composition containing levornidazole and a preparation method of the pharmaceutical composition. The preparation medicine composition is prepared from the following components in parts by weight: 1 part of levornidazole, 0.1 to 0.14 part of corn starch, 0.05 to 0.07 part of carboxymethyl starch sodium, 0.006 to 0.007 part of hydroxypropyl methylcellulose and 0.006 to 0.01 part of magnesium stearate. By means of the synergistic effect of specific auxiliary materials and precise control over the particle size of the levornidazole raw material medicine, the preparation has excellent stability, the treatment effect of levornidazole can be effectively improved, and the adverse reaction of medication is reduced.

The invention relates to a crystal of a nitroimidazole compound as well as a preparation method and application thereof, in particular to a crystal I, a crystal II and a crystal III of S-ornidazole disodium phosphate, and further relates to application of the crystals in preparation of anti-anaerobe infection drugs and anti-protozoan drugs.